ARTICLE | Clinical News
Zoladex goserelin: Phase III data
April 11, 2005 7:00 AM UTC
Results from a 10-year Phase III study in 977 patients showed that the administration of goserelin after radiation therapy reduced prostate cancer progression and significantly improved survival. Surv...